Urgent Policy Statement: Cystic Fibrosis Modulator Therapies

Source:
NHS England
Publisher:
NHS England
Publication date:
11 November 2019

Abstract

This policy states that NHS England will now routinely fund ivacaftor, lumacaftor/ivacaftor, and tezacaftor/ivacaftor for patients in England. They should only be prescribed by physicians with experience in the treatment of CF working within NHS England commissioned CF services.